Session » Rheumatoid Arthritis - Clinical Aspects Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 448

A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care

9:00AM-11:00AM: Abstract Number: 491

A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing

9:00AM-11:00AM: Abstract Number: 432

Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-

9:00AM-11:00AM: Abstract Number: 430

Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA

9:00AM-11:00AM: Abstract Number: 483

Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 515

Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 452

Associations Between Arthritis Patient, Disease-Specific and Provider Characteristics and Medication Information Source Use

9:00AM-11:00AM: Abstract Number: 475

Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 464

Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 449

Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)

9:00AM-11:00AM: Abstract Number: 501

Change in RF Titers Reflects RA Disease Activity and Predicts Therapeutic Response during TNF Inhibitor Therapy; Patients with a Continuous Reduction of Serum RF Levels Show Good Response

9:00AM-11:00AM: Abstract Number: 460

Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 468

Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria

9:00AM-11:00AM: Abstract Number: 440

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment

9:00AM-11:00AM: Abstract Number: 476

Clinical Disease Activity Measures Change Substantially and Irregularly over Time in Individual Rheumatoid Arthritis Patients Considered to be in Steady State

9:00AM-11:00AM: Abstract Number: 466

Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis

9:00AM-11:00AM: Abstract Number: 467

Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values

9:00AM-11:00AM: Abstract Number: 480

Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 505

Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry

9:00AM-11:00AM: Abstract Number: 438

Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 447

Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status

9:00AM-11:00AM: Abstract Number: 492

Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 513

Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans

9:00AM-11:00AM: Abstract Number: 502

Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets

9:00AM-11:00AM: Abstract Number: 493

Diagnostic Delay in Early Arthritis: Ten Years-Experience of a Single Center

9:00AM-11:00AM: Abstract Number: 456

Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 470

Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components

9:00AM-11:00AM: Abstract Number: 443

Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register

9:00AM-11:00AM: Abstract Number: 489

Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic

9:00AM-11:00AM: Abstract Number: 434

Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 487

Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function

9:00AM-11:00AM: Abstract Number: 499

Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity

9:00AM-11:00AM: Abstract Number: 451

Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman

9:00AM-11:00AM: Abstract Number: 482

Erosions in the Foot at Baseline Are Predictive of Orthopedic Shoe Use after 10 Years of Treat to Target Therapy

9:00AM-11:00AM: Abstract Number: 461

Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 485

Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 506

Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 458

First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network

9:00AM-11:00AM: Abstract Number: 494

High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 453

Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 510

Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare

9:00AM-11:00AM: Abstract Number: 479

How to Recruit Anti-CCP Positive Patients from Primary Care

9:00AM-11:00AM: Abstract Number: 516

Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?

9:00AM-11:00AM: Abstract Number: 471

Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab

9:00AM-11:00AM: Abstract Number: 478

Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 508

Impact of Race on Patient Global Scores and the Misclassification of Disease Activity

9:00AM-11:00AM: Abstract Number: 435

Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)

9:00AM-11:00AM: Abstract Number: 509

In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters

9:00AM-11:00AM: Abstract Number: 496

Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate

9:00AM-11:00AM: Abstract Number: 504

Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment

9:00AM-11:00AM: Abstract Number: 517

Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 437

Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry

9:00AM-11:00AM: Abstract Number: 446

Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate

9:00AM-11:00AM: Abstract Number: 507

Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 473

Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 465

MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 514

MRI Bone Oedema at Enrollment Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 454

No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 498

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey

9:00AM-11:00AM: Abstract Number: 500

Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 477

On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients

9:00AM-11:00AM: Abstract Number: 486

Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort

9:00AM-11:00AM: Abstract Number: 445

Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 490

Personalizing the Treat to Target Approach in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 512

Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?

9:00AM-11:00AM: Abstract Number: 503

Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients

9:00AM-11:00AM: Abstract Number: 455

Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care

9:00AM-11:00AM: Abstract Number: 511

Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient

9:00AM-11:00AM: Abstract Number: 495

Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy

9:00AM-11:00AM: Abstract Number: 439

Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials

9:00AM-11:00AM: Abstract Number: 472

Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?

9:00AM-11:00AM: Abstract Number: 457

RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics

9:00AM-11:00AM: Abstract Number: 484

Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use

9:00AM-11:00AM: Abstract Number: 462

Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades

9:00AM-11:00AM: Abstract Number: 433

Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population

9:00AM-11:00AM: Abstract Number: 488

Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 459

The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry

9:00AM-11:00AM: Abstract Number: 427

The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 481

Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience

9:00AM-11:00AM: Abstract Number: 444

TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database

9:00AM-11:00AM: Abstract Number: 497

Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry

9:00AM-11:00AM: Abstract Number: 429

Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment

9:00AM-11:00AM: Abstract Number: 431

Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission

9:00AM-11:00AM: Abstract Number: 463

Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders

9:00AM-11:00AM: Abstract Number: 474

Trends in the Use of Opiates in Rheumatoid Arthritis (RA) Compared to Non-RA: A Population Based Study in 2003-2012

9:00AM-11:00AM: Abstract Number: 436

Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?

9:00AM-11:00AM: Abstract Number: 441

Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 442

Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 428

Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry

9:00AM-11:00AM: Abstract Number: 450

Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial

9:00AM-11:00AM: Abstract Number: 469

Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].